Quantcast
Home > Quotes > GNCA
x

Genocea Biosciences, Inc. Common Stock (GNCA) Quote & Summary Data

GNCA 
$0.724
*  
0.0162
2.19%
Get GNCA Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading GNCA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 0.75 / $ 0.70
Share Volume
268,261
50 Day Avg. Daily Volume
411,317
Previous Close
$ 0.7402
52 Week High / Low
$ 1.52 / $ 0.49
Market Cap
62,717,206
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
268,261
50 Day Avg. Daily Volume:
411,317

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.22

Trading Range

The current last sale of $0.724 is 47.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.75 $ 1.52
 Low: $ 0.70 $ 0.49

Company Description (as filed with the SEC)

Unless the context requires otherwise, references in this Annual Report on Form 10-K to "Genocea", "we", "us" and "our" refer to Genocea Biosciences, Inc. Overview We are a biopharmaceutical company that discovers and develops novel cancer vaccines. We use our proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. We believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, we announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of our research programs and product candidates in active development are at the preclinical stage.  ... More ...  


Risk Grade

Where does GNCA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.7399
Open Date:
Oct. 19, 2018
Close Price:
$ 0.724
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info